| Neural stem cells display extensive tropism for pathology in adult brain: evidence from intracranial gliomas KS Aboody, A Brown, NG Rainov, KA Bower, S Liu, W Yang, JE Small, ... Proceedings of the National Academy of Sciences 97 (23), 12846-12851, 2000 | 1694 | 2000 |
| Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre … R Stupp, ME Hegi, T Gorlia, SC Erridge, J Perry, YK Hong, KD Aldape, ... The lancet oncology 15 (10), 1100-1108, 2014 | 1067 | 2014 |
| High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial E Thiel, A Korfel, P Martus, L Kanz, F Griesinger, M Rauch, A Röth, ... The lancet oncology 11 (11), 1036-1047, 2010 | 680 | 2010 |
| Primary central nervous system lymphomas (PCNSL): MRI features at presentation in 100 patients W Küker, T Nägele, A Korfel, S Heckl, E Thiel, M Bamberg, M Weller, ... Journal of neuro-oncology 72, 169-177, 2005 | 518 | 2005 |
| Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA–09): a … U Herrlinger, T Tzaridis, F Mack, JP Steinbach, U Schlegel, M Sabel, ... The lancet 393 (10172), 678-688, 2019 | 514 | 2019 |
| SD-208, a novel transforming growth factor β receptor I kinase inhibitor, inhibits growth and invasiveness and enhances immunogenicity of murine and human glioma cells in vitro … M Uhl, S Aulwurm, J Wischhusen, M Weiler, JY Ma, R Almirez, ... Cancer research 64 (21), 7954-7961, 2004 | 501 | 2004 |
| MRI features of primary central nervous system lymphomas at presentation U Buhring, U Herrlinger, T Krings, R Thiex, M Weller, W Kuker Neurology 57 (3), 393-396, 2001 | 419 | 2001 |
| Diagnosis and treatment of primary CNS lymphoma in immunocompetent patients: guidelines from the European Association for Neuro-Oncology K Hoang-Xuan, E Bessell, J Bromberg, AF Hottinger, M Preusser, R Rudà, ... The Lancet Oncology 16 (7), e322-e332, 2015 | 398 | 2015 |
| Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3 … MJ van den Bent, B Baumert, SC Erridge, MA Vogelbaum, AK Nowak, ... The Lancet 390 (10103), 1645-1653, 2017 | 395 | 2017 |
| MGMT promoter methylation is a strong prognostic biomarker for benefit from dose-intensified temozolomide rechallenge in progressive glioblastoma: the DIRECTOR trial M Weller, G Tabatabai, B Kästner, J Felsberg, JP Steinbach, A Wick, ... Clinical cancer research 21 (9), 2057-2064, 2015 | 385 | 2015 |
| Efficacy and tolerability of temozolomide in an alternating weekly regimen in patients with recurrent glioma A Wick, J Felsberg, JP Steinbach, U Herrlinger, M Platten, B Blaschke, ... Journal of Clinical Oncology 25 (22), 3357-3361, 2007 | 337 | 2007 |
| Primary intraocular lymphoma: an international primary central nervous system lymphoma collaborative group report SA Grimm, JS Pulido, K Jahnke, D Schiff, AJ Hall, TN Shenkier, T Siegal, ... Annals of oncology 18 (11), 1851-1855, 2007 | 295 | 2007 |
| Complete resection of contrast-enhancing tumor volume is associated with improved survival in recurrent glioblastoma—results from the DIRECTOR trial B Suchorska, M Weller, G Tabatabai, C Senft, P Hau, MC Sabel, ... Neuro-oncology 18 (4), 549-556, 2016 | 277 | 2016 |
| Diagnosis of pseudoprogression in patients with glioblastoma using O-(2-[18F]fluoroethyl)-l-tyrosine PET N Galldiks, V Dunkl, G Stoffels, M Hutterer, M Rapp, M Sabel, ... European journal of nuclear medicine and molecular imaging 42, 685-695, 2015 | 266 | 2015 |
| Adjuvant and concurrent temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): second interim analysis of a randomised, open-label, phase 3 … MJ van den Bent, CMS Tesileanu, W Wick, M Sanson, AA Brandes, ... The Lancet Oncology 22 (6), 813-823, 2021 | 245 | 2021 |
| Vessel wall contrast enhancement: a diagnostic sign of cerebral vasculitis W Küker, S Gaertner, T Nägele, C Dopfer, M Schöning, J Fiehler, ... Cerebrovascular Diseases 26 (1), 23-29, 2008 | 243 | 2008 |
| Primary CNS lymphoma with intraocular involvement: international PCNSL collaborative group report SA Grimm, CA McCannel, AMP Omuro, AJM Ferreri, JY Blay, EA Neuwelt, ... Neurology 71 (17), 1355-1360, 2008 | 239 | 2008 |
| German Cancer Society Neuro‐Oncology Working Group NOA‐03 multicenter trial of single‐agent high‐dose methotrexate for primary central nervous system lymphoma U Herrlinger, M Schabet, W Brugger, RD Kortmann, W Küker, M Deckert, ... Annals of Neurology: Official Journal of the American Neurological …, 2002 | 217 | 2002 |
| NOA‐03 trial of high‐dose methotrexate in primary central nervous system lymphoma U Herrlinger, W Küker, M Uhl, HP Blaicher, HO Karnath, L Kanz, ... Annals of Neurology: Official Journal of the American Neurological …, 2005 | 212 | 2005 |
| Relapse of primary central nervous system lymphoma: clinical features, outcome and prognostic factors K Jahnke, E Thiel, P Martus, U Herrlinger, M Weller, L Fischer, A Korfel, ... Journal of neuro-oncology 80, 159-165, 2006 | 209 | 2006 |
